89bio, Inc. financial data

Symbol
ETNB on Nasdaq
Industry
Pharmaceutical Preparations
Location
655 Montgomery Street, Suite 1500, San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.35K % -30.9%
Debt-to-equity 16.2 % +42.2%
Return On Equity -81.4 % -162%
Return On Assets -70 % -152%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 146M shares +48.4%
Common Stock, Shares, Outstanding 120M shares +28.5%
Entity Public Float 722M USD -38.6%
Common Stock, Value, Issued 120K USD +29%
Weighted Average Number of Shares Outstanding, Basic 105M shares +47.1%
Weighted Average Number of Shares Outstanding, Diluted 105M shares +47.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 345M USD +182%
General and Administrative Expense 39.6M USD +36.7%
Operating Income (Loss) -385M USD -154%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -366M USD -165%
Income Tax Expense (Benefit) 692K USD -82.1%
Net Income (Loss) Attributable to Parent -367M USD -158%
Earnings Per Share, Basic -3.51 USD/shares -75.5%
Earnings Per Share, Diluted -3.51 USD/shares -75.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 126M USD -60.1%
Marketable Securities, Current 314M USD +19.5%
Cash, Cash Equivalents, and Short-term Investments 440M USD -24%
Assets, Current 476M USD -19.7%
Property, Plant and Equipment, Net 23K USD -50%
Operating Lease, Right-of-Use Asset 1.57M USD -31.4%
Other Assets, Noncurrent 640K USD +61.6%
Assets 479M USD -19.7%
Accounts Payable, Current 15.4M USD +79.2%
Employee-related Liabilities, Current 6.87M USD +9.99%
Accrued Liabilities, Current 20M USD -2.48%
Liabilities, Current 36.1M USD +22%
Operating Lease, Liability, Noncurrent 1.09M USD -40%
Other Liabilities, Noncurrent 4.43M USD +18.4%
Liabilities 77.9M USD +29.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 563K USD +196%
Retained Earnings (Accumulated Deficit) -825M USD -80.2%
Stockholders' Equity Attributable to Parent 401M USD -25.3%
Liabilities and Equity 479M USD -19.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.7M USD -32%
Net Cash Provided by (Used in) Financing Activities 21M USD -93.5%
Net Cash Provided by (Used in) Investing Activities -79.9M USD -2046%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 120M shares +28.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -98.6M USD -133%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 126M USD -60.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 679K USD +25.3%
Deferred Tax Assets, Valuation Allowance 215M USD +98.3%
Deferred Tax Assets, Gross 215M USD +97.4%
Operating Lease, Liability 1.82M USD -21.4%
Depreciation 9K USD -35.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -367M USD -159%
Lessee, Operating Lease, Liability, to be Paid 2.09M USD -27%
Operating Lease, Liability, Current 727K USD +46.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 937K USD +2.18%
Lessee, Operating Lease, Liability, to be Paid, Year One 917K USD +18.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 277K USD -50.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 240K USD -74.4%
Deferred Tax Assets, Operating Loss Carryforwards 89.3M USD +42%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 16.8M USD +39.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 240K USD
Additional Paid in Capital 1.08B USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 516K USD -27.8%
Share-based Payment Arrangement, Expense 20.6M USD +28.1%
Interest Expense 5.29M USD +10.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%